VEOPOZ

Registered
Word Mark

Key Information

Serial Number

Registration Number

Status

Registered

Ownership

RP

Owner Name

Type: Organization / Corporation

Address

777 Old Saw Mill River Road
Tarrytown, NY 10591

Critical Dates

First Use Date

Oct 19, 2023

Filing Date

Mar 8, 2022

Registration Date

Jan 9, 2024

Mark Descriptions

Goods

Class 5
Pharmaceutical preparations for the treatment of immunological, autoimmune, and genetic diseases and disorders

Mark Elements

Text Mark
VEOPOZ
Category
Trademark
Standard Characters
Yes
Color Claim
No
Data source: USPTO TSDR
View on USPTO website

Trademark Timeline

First Use

Oct 19, 2023

Filing Date

Mar 8, 2022

Publication Date

Jan 24, 2023

Registration Date

Jan 9, 2024

USPTO Records

TitleDateCategorySourcePagesFormatActions

AI AssessmentCached Mar 12, 2026, 08:55 AM
Cached

AI-generated analysis of USPTO data for this trademark. WARNING: Content may not be accurate or up to date. Validate all responses.

Trademark Summary

VEOPOZ is a standard character word mark owned by Regeneron Pharmaceuticals, Inc., a New York corporation, covering pharmaceutical preparations for the treatment of immunological, autoimmune, and genetic diseases and disorders in International Class 005, with additional domestic classes 006, 018, 044, 046, 051, and 052. The mark is registered on the Principal Register as of January 9, 2024, with registration number 7271822. It originated as a divisional child application from serial number 97301520, and class 005 is active.

Recent Activity

Filed on March 8, 2022, the application was published for opposition on January 24, 2023, followed by a Notice of Allowance on March 21, 2023. A statement of use was filed October 30, 2023, leading to registration on January 9, 2024; recent changes include attorney revocation/appointment and owner address updates on June 30, 2025.
USPTO
AI Analysis
v2.8.0
Generated Mar 12, 2026, 08:55 AM

Never miss important updates for this trademark

Get instant alerts when status changes, similar marks are filed, or renewal deadlines approach

Cookie Preferences

We use cookies (including Google Analytics) to improve our site and understand how visitors use it.